Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results

Kezar Life Sciences (NASDAQ:KZR) issued its earnings results on Tuesday. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06), Zacks reports.

Kezar Life Sciences Stock Down 10.1 %

NASDAQ KZR opened at $5.54 on Wednesday. Kezar Life Sciences has a twelve month low of $5.20 and a twelve month high of $9.53. The stock has a market cap of $40.39 million, a PE ratio of -0.43 and a beta of 0.49. The firm has a 50-day simple moving average of $6.07 and a 200 day simple moving average of $6.71. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KZR. HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd. Wells Fargo & Company reduced their price objective on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, December 19th. Finally, William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.